Dynavax Technologies Dirección

Dirección controles de criterios 3/4

El CEO de Dynavax Technologies' es Ryan Spencer , nombrado en Dec 2019, tiene una permanencia de 4.33 años. compensación anual total es $5.81M, compuesta por 13.1% salario y 86.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.18% de las acciones de la empresa, por valor de $2.57M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.8 años, respectivamente.

Información clave

Ryan Spencer

Chief Executive Officer (CEO)

US$5.8m

Compensación total

Porcentaje del salario del CEO	13.1%
Permanencia del CEO	4.4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ryan Spencer en comparación con los beneficios de Dynavax Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$9m
Dec 31 2023	US$6m	US$760k	-US$6m
Sep 30 2023	n/a	n/a	US$61m
Jun 30 2023	n/a	n/a	US$111m
Mar 31 2023	n/a	n/a	US$236m
Dec 31 2022	US$6m	US$695k	US$293m
Sep 30 2022	n/a	n/a	US$320m
Jun 30 2022	n/a	n/a	US$228m
Mar 31 2022	n/a	n/a	US$104m
Dec 31 2021	US$5m	US$600k	US$72m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$62m
Dec 31 2020	US$2m	US$515k	-US$75m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	n/a	n/a	-US$138m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$3m	US$391k	-US$156m

Compensación vs. Mercado: La compensación total de Ryan($USD5.81M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.33M).

Compensación vs. Ingresos: La compensación de Ryan ha sido consistente con los resultados de la empresa en el último año.

CEO

Ryan Spencer (45 yo)

4.4yrs

Permanencia

US$5,810,736

Compensación

Mr. Ryan Spencer serves as Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He serves as the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ryan Spencer	CEO, Interim CFO & Director	4.4yrs	US$5.81m	0.18% $ 2.5m
David Novack	President & COO	11.2yrs	US$2.99m	0.024% $ 342.5k
Robert Janssen	Chief Medical Officer and Senior VP of Clinical Development	10.8yrs	US$1.88m	0.049% $ 689.5k
Kelly MacDonald	Senior VP & CFO (Leave of Absence)	less than a year	US$2.07m	0.0059% $ 82.6k
Justin Burgess	Chief Accounting Officer & Controller	4yrs	sin datos	sin datos
Jeff Coon	Senior VP & Chief Human Resources Officer	5.3yrs	sin datos	sin datos
Paul Cox	VP of Investor Relations & Corporate Communications	1.3yrs	sin datos	sin datos
John Slebir	Senior VP & General Counsel	2.9yrs	sin datos	sin datos
Donn Casale	Senior VP & Chief Commercial Officer	no data	sin datos	sin datos
Dong Yu	Senior Vice President of Vaccine Research	3.3yrs	sin datos	sin datos
Eric Frings	VP, Site Head & MD for Dynavax GmbH	3.3yrs	sin datos	sin datos
Todd Lopeman	Senior Vice President of Technical Operations	3.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0IDA se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ryan Spencer	CEO, Interim CFO & Director	4.4yrs	US$5.81m	0.18% $ 2.5m
Peggy Phillips	Independent Director	17.8yrs	US$298.73k	0.021% $ 297.6k
Daniel Kisner	Independent Director	13.8yrs	US$290.73k	0.0011% $ 16.2k
Francis Cano	Independent Director	14.5yrs	US$278.73k	0.016% $ 223.6k
Robert Coffman	Member of Scientific Advisory Board	1.3yrs	US$1.83m	sin datos
Drew Pardoll	Member of Scientific Advisory Board	5.9yrs	sin datos	sin datos
Julie Eastland	Independent Director	3.8yrs	US$293.73k	0% $ 0
Stanley Plotkin	Member of Scientific Advisory Board	5.9yrs	US$20.00k	sin datos
Scott Myers	Independent Chairman of the Board	2.6yrs	US$323.73k	0% $ 0
Miriam Merad	Member of Scientific Advisory Board	5.9yrs	sin datos	sin datos
Laura Q. Chow	Member of Scientific Advisory Board	5.9yrs	sin datos	sin datos
E. Wherry	Member of Scientific Advisory Board	5.9yrs	sin datos	sin datos

5.9yrs

Permanencia media

72.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0IDA se considera experimentada (5.8 años de antigüedad promedio).

Dynavax Technologies Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

President & COO recently sold US$191k worth of stock

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

High number of new directors

Recent updates

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.19 loss in 1Q 2023)

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.05 loss per share (vs US$2.32 profit in FY 2022)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.50 in 3Q 2022)

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.027 (vs US$1.02 in 2Q 2022)

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment improves as stock rises 16%

President & COO recently sold US$191k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.26 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$2.32 (vs US$0.62 in FY 2021)

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Now 22% undervalued

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$1.02 (vs US$0.039 in 2Q 2021)

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Dynavax Technologies Corporation Reaffirms Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.26 (vs US$0.007 in 1Q 2021)

Dynavax Technologies Corporation to Report Q1, 2022 Results on May 05, 2022

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dynavax Technologies Corporation Provides Revenue Guidance for the Full Year 2022

Dynavax Technologies Corporation to Report Q4, 2021 Results on Feb 28, 2022

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.04 profit in 3Q 2020)

Forecast to breakeven in 2021

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: EPS US$0.039 (vs US$0.53 loss in 2Q 2020)

High number of new directors

Dynavax Technologies Corporation(NasdaqCM:DVAX) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.008 (vs US$0.15 loss in 1Q 2020)

Full year 2020 earnings released: US$0.75 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Dynavax Technologies Corporation Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Technologies Corporation to Report Q4, 2020 Results on Feb 25, 2021

Dong Yu Joins in Dynavax Technologies Corporation as Senior Vice President of Vaccine Research and A Member of the Executive Team

Dynavax Technologies Corporation and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Dynavax Technologies Corporation Enters into an Agreement with the Coalition for Epidemic Preparedness Innovations

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Dynavax Technologies Corporation Appoints Kelly Macdonald as Its Senior Vice President and Principal Financial Officer, Effective March 1, 2021

Dynavax Technologies Corporation Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Serum Institute of India Partneres with Dynavax Technologies Corporation Jointly Announces First Participants Dosed in the Phase 1/2 Clinical Trial for a Covid-19 Vaccine

European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine

Third quarter 2020 earnings released: EPS US$0.04

Revenue beats expectations

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

Dynavax Technologies Corporation Announces Management Changes

Dynavax Technologies Corporation to Report Q2, 2020 Results on Aug 06, 2020

Análisis de compensación del CEO

CEO

Permanencia